p8 is a new target of gemcitabine in pancreatic cancer cells

Clinical Cancer Research

Volumn 12, Issue 1, 2006, Pages 235-241

  Giroux, Valentin ^a   Malicet, Cédric ^a   Barthet, Marc ^a   Gironella, Meritxell ^a   Archange, Cendrine ^a   Dagorn, Jean Charles ^a   Vasseur, Sophie ^a   Iovanna, Juan L ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GEMCITABINE; HEAT SHOCK PROTEIN; MESSENGER RNA; PROTEIN P8; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DNA MICROARRAY; EMBRYO; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 31544450585     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1700     Document Type: Article

References (35)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J Clin 2003;53:5-26.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57
3. Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, Verslype C. Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 2004;16:265-74.
4. Schultz RM, Merriman RL, Toth JE, et al. Evaluation of new anticancer agents against the MlA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 1993;5:223-8.
5. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261-8.
6. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.
7. Vasseur S, Hoffmeister A, Garcia-Montero A, et al. p8-deficient fibroblasts grow more rapidly and are more resistant to Adriamycin-induced apoptosis. Oncogene 2002;21:1685-94.
8. Vasseur S, Vidal Mallo G, Fiedler F, et al. Cloning and expression of the human p8, a nuclear protein with mitogenic activity. Eur J Biochem 1999;259:670-5.
9. Vasseur S, Hoff meister A, Garcia S, Bagnis C, Dagorn JC, Iovanna JL. p8 is critical for tumour development induced by rasV12 mutated protein and E1A oncogene. EMBO Rep 2002;3:165-70.
10. Vasseur S, Hoffmeister A, Garcia-Montero A, et al. Mice with targeted disruption of p8 gene show increased sensitivity to lipopolysaccharide and DNA microarray analysis of livers reveals an aberrant gene expression response. BMC Gastroenterol 2003;3:25.
11. Vasseur S, Folch-Puy E, Hlouschek V, et al. p8 improves pancreatic response to acute pancreatitis by enhancing the expression of the anti-inflammatory protein pancreatitis-associated protein I. J Biol Chem 2004;279:7199-207.
12. Mallo GV, Fiedler F, Calvo EL, et al. Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. J Biol Chem 1997;272:32360-9.
13. Garcia-Montero A, Vasseur S, Mallo GV, Soubeyran P, Dagorn JC, Iovanna JL. Expression of the stress-induced p8 mRNA is transiently activated after culture medium change. Eur J Cell Biol 2001;80:720-5.
14. Nabhan C, Gajria D, Krett NL, Gandhi V, Ghias K, Rosen ST. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther 2002;1:1221-7.
15. DiMagno EP, Reber HA, Tempero MA. A technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gasroenterological Association. Gastroenterology 1999;117:1464-84.
16. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
17. Buchler M, Friess H, Schultheiss KH, et al. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 1991;68:1507-12.
18. Friess H, Buchler M, Kruger M, Beger HG. Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin. Pancreas 1992;7:516-21.
19. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995;86:1903-10.
20. Mattii L, Barale R, Petrini M. Use of the comet test in the evaluation of multidrug resistance of human cell lines. Leukemia 1998;12:627-32.
21. Ree AH, Pacheco MM, Tvermyr M, Fodstad O, Brentani MM. Expression of a novel factor, com1, in early tumor progression of breast cancer. Clin Cancer Res 2000;6:1778-83.
22. Su SB, Motoo Y, Iovanna JL, et al. Expression of p8 in human pancreatic cancer. Clin Cancer Res 2001;7:309-13.
23. Ito Y, Yoshida H, Motoo Y et al. Expression and cellular localization of p8 protein in thyroid neoplasms. Cancer Lett 2003;201:237-44.
24. Su SB, Motoo Y, Iovanna JL, et al. Overexpression of p8 is inversely correlated with apoptosis in pancreatic cancer. Clin Cancer Res 2001;7:1320-4.
25. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000;60:5451-5.
26. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun 2003;311:786-92.
27. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res 2005;11:3433-8.
28. Habiro A, Tanno S, Koizumi K, et al. Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun 2004;316:71-7.
29. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243-51.
30. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004;10:2307-18.
31. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 1999;6:279-85.
32. Xu Z, Friess H, Solioz M, et al. Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer 2001;94:268-74.
33. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004;23:1539-48.
34. Kroep JR, Loves WJ, van der Wilt CL, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002;1:371-6.
35. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002;5:19-33.